News | June 10, 2024
Neuland unveils refreshed brand identity
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Subscribe To Our Newsletter & Stay Updated
